Board approves half-year results and declares interim dividend
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited financial results for the half year ended September 30, 2026, including the profit and loss, assets and liabilities, and cash flow statements. The results were reviewed by statutory auditors SKLR and Co. LLP and the Audit Committee. An interim dividend of Rs 0.50 per share, equal to 5 percent of face value, was declared for 2026-27. The record date is October 30, 2026, and payment is due within 30 days.
The dividend may support shareholder returns, but the filing gives no profit, revenue, debt, or cash-flow figures to assess the results' effect on the share price.